Promethera Biosciences to Attend and Present at Upcoming Scientific and Partnering Conferences in March and April

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced that the Company will give presentations and attend the following scientific and partnering conferences in Japan, Europe, and the US.

18^th Congress of the Japanese Society for Regenerative Medicine
Date: March 21-23, 2019
Venue: JSRM Convention Center, Kobe, Japan
Breakfast seminar on liver regeneration by allogenic mesenchymal stem cell therapy:

Session 1: Mesenchymal stem cells derived from adult human liver: an attractive expandable cell source to target hepatic deficiencies
Presenter: Mustapha Najimi, Special Advisor – Scientific Affairs

Session 2: HepaStem, adult liver mesenchymal stem cells for liver rescue therapy in ACLF and NASH
Presenter: Prof. Etienne Sokal, M.D., Ph.D., CMO/CSO
Date: March 23^rd, 2019

BioEurope Spring
Date: March 25-27, 2019
Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria
Panel:

Title: “What’s NEXT in NASH?”
Presenter: Pascale Jordan, Ph.D. Director BD, External Evaluation
Date: March 25^th, 2019

The International Liver Congress™ 2019 (EASL)
Date: April 10-14, 2019
Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria
Booth: Biotech Village booth #6

3^rd Annual NASH Summit in Boston
Date: April 22-25, 2019
Venue: Hilton Boston Logan Airport, Boston, MA, USA
Presentation:

Title: “HepaStem for the treatment of fibro-inflammatory liver diseases”
Date: April 22, 2019
Presenter: Nathalie Belmonte, Ph.D., VP Product Development

Cell & Gene Meeting on the Mediterranean
Date: April 23-25, 2019
Venue: Hotel Arts Barcelona, Barcelona, Spain
Panel:

Title: “Recent developments and predictions for the future of advanced therapies”
Presenter: John Tchelingerian, Ph.D., President & CEO

Company presentation:

Title: “HepaStem, adult liver medicinal signaling cells for liver rescue therapy in ACLF and NASH”
Presenter: Prof. Etienne Sokal, M.D., Ph.D., CMO/CSO
Date: April 24^rd, 2019

About Promethera Biosciences

Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring life-saving treatments to reduce the need for liver transplantation. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline we develop antibody technologies, such as the antiTNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert, Belgium, Durham, NC, USA, Tokyo, Japan and Basel, Switzerland.

Promethera®, HepaStem®, H2stem®, are all registered trademarks of the PROMETHERA group.

https://www.linkedin.com/company/promethera-biosciences

https://twitter.com/Promethera

View source version on businesswire.com: https://www.businesswire.com/news/home/20190312005122/en/